Participants 68 104 5
patients with low ejection fractions
Participants 349 398 6
6797 patients with ejection fractions < or = 0.35
Participants 647 785 5
Patients with heart failure entered the treatment trial (n = 2569) and those without heart failure entered the prevention trial (n = 4228)
Participants 1107 1133 5
362 placebo group patients
Participants 1250 1276 4
595 placebo group patients
Participants 1317 1343 4
499 in the enalapril group
Participants 1757 1793 5
patients with low ejection fractions
